Mouse and fly models of neurodegeneration

Trends in Genetics

Volumn 18, Issue 9, 2002, Pages 463-471

  Zoghbi, Huda Y ^a   Botas, Juan ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Program in Developmental Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; POLYGLUTAMINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CLEARANCE; DEGENERATIVE DISEASE; FLY; HUNTINGTON CHOREA; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE REPEAT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SPINOCEREBELLAR DEGENERATION; TRANSGENIC ANIMAL;

ANIMALS; DIPTERA; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEURODEGENERATIVE DISEASES;

ANIMALIA;

EID: 0036720019     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(02)02729-4     Document Type: Review

References (82)

1. Fourteen and counting: Unraveling trinucleotide repeat diseases
2. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein
3. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes
4. SCA1 transgenic mice: A model for neurodegeneration caused by an expanded CAG trinucleotide repeat
5. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo
6. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
7. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila
8. Identification of genes that modify ataxin-1-induced neurodegeneration
9. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock- in mice
10. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the sca1 locus
11. Neurological abnormalities in a knock-in mouse model of Huntington's disease
12. A long CAG tract in the mouse Sca1 locus replicates human SCA1 and reveals the impact of mutant protein solubility on selective neuronal vulnerability
13. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
14. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro
15. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70
16. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice
17. Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance
18. The chaperone function of hsp70 is required for protection against stress-induced apoptosis
19. Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation
20. Genetic suppression of polyglutamine toxicity in Drosophila
21. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
22. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
23. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription
24. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin
25. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
26. CREB-binding protein sequestration by expanded polyglutamine
27. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
28. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types
29. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
30. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
31. Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ
32. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice
33. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes
34. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
35. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils
36. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse
37. Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles
38. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
39. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice
40. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)
41. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
42. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau
43. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding
44. Tau in paired helical filaments is functionally distinct from fetal tau: Assembly incompetence of paired helical filament-tau
45. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding
46. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice
47. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice
48. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice
49. The genetics of Parkinson's disease
50. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
51. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
52. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
53. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin- 1: Implications for Lewy-body formation in Parkinson disease
54. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease
55. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin
56. Parkin and the molecular pathways of Parkinson's disease
57. Neuropathology of synuclein aggregates
58. A Drosophila model of Parkinson's disease
59. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
60. Neuropathology in mice expressing human alpha-synuclein
61. Subcellular localization of wild-type and Parkinson's disease- associated mutant alpha -synuclein in human and transgenic mouse brain
62. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease
63. β-Synuclein inhibits alpha-synuclein aggregation: A possible role as an anti-parkinsonian factor
64. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
65. Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA
66. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease
67. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
68. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons
69. Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion
70. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
71. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease
72. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform
73. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein
74. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein
75. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
76. Tau filament formation in transgenic mice expressing P301L tau
77. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau
78. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau
79. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain
80. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila
81. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53-Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice
82. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein